Chinese Medicine in combination with western medicine for the prevention of relapse in patients with severe psoriasis
Phase 1
Not yet recruiting
- Conditions
- Psoriasis
- Registration Number
- ITMCTR2000003295
- Lead Sponsor
- Guangdong Hospital of traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. The patients with psoriatic lesions area and severity index PASI = 10 met the diagnostic criteria of severe psoriasis;
2. Patients who meet the indications of biological agents (iqizhu) and have no history of inflammatory bowel disease (IBD);
3. Patients who sign informed consent.
Exclusion Criteria
Psoriasis patients not suitable for iqizhu treatment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the combination of Gu-Ben Hua-Yu-fang with ixekizumab in psoriasis treatment?
How does the efficacy of Gu-Ben Hua-Yu-fang plus ixekizumab compare to standard-of-care biologics for severe psoriasis?
Which biomarkers are associated with response to Chinese herbal medicine and IL-17 inhibition in psoriatic patients?
What are the potential adverse events and management strategies for integrating traditional Chinese medicine with ixekizumab in psoriasis?
Are there alternative combination therapies for severe psoriasis involving IL-17 inhibitors and herbal formulations?